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Potassium dichromate [Cr(VI)] is the most 
toxic form of chromium produced by indus-
trial processes and is a common environmen-
tal contaminant (Langard 1990). Humans 
exposed to Cr(VI) under environmental or 
occupational settings show increased risk of 
asthma, nasal septum and skin ulcerations, 
allergic and contact dermatitis, and respira-
tory cancers (Salnikow and Zhitkovich 2008). 
Experimental mice exposed to chromate 
exhibit acute tissue damage, including testicu-
lar lesions, kidney tubular necrosis, and liver 
toxicity, whereas Cr(VI) ingestion via drink-
ing water leads to increased DNA damage 
and ultraviolet-induced skin tumor formation 
in mice (Davidson et al. 2004; Ueno et al. 
2001). In addition, Cr(VI) is a developmental 
toxicant that causes developmental defects, 
including postimplantation losses, resorp-
tions, reduced fetal weight, and malforma-
tions (Junaid et al. 1996; Kanojia et al. 1998). 
Particulate Cr(VI) undergoes dissolution 
on the cell surface, and the chromate oxyan-
ion enters the cells through the nonspecific 
phosphate/sulfate ion transporters (O’Brien 
et al. 2003). Once inside the cell, chromate 
can be rapidly reduced by antioxidants, such as 
ascorbate, glutathione, and NAD(P)H, to gen-
erate reactive Cr(V) and Cr(IV) intermediates 
that are strong oxidants. The Cr intermediates 
are subsequently reduced to form the thermo-
dynamically stable Cr(III), which is primarily 
responsible for DNA adducts formation and 
mutagenicity (Salnikow and Zhitkovich 2008). 
On the other hand, Cr(VI) has been shown 
to activate cellular signaling pathways that in 
turn lead to either promoting (Salnikow and 
Zhitkovich 2008; Wakeman et al. 2005; Wang 
and Shi 2001) or preventing Cr(VI) toxicity 
(Chen et al. 2002; He et al. 2007). 
One group of signaling factors activated by 
Cr(VI) is the mitogen-activated protein kinases 
(MAPKs) (Chuang and Yang 2001; Tessier 
and Pascal 2006). MAPKs are cytosolic Ser/Thr 
protein kinases, comprising the extracellular 
signal-regulated kinase (ERK) (ERK1/2), c-Jun 
N-terminal kinase (JNK) (1/2/3), and p38 
(α/β/γ/δ) subfamilies. Activation of the MAPKs 
is mediated through the specific upstream MAP 
kinase kinases (MAP2Ks) (Robinson and Cobb 
1997). Whereas the MAP2K4 and MAP2K7 
are the upstream kinases for JNK activation, 
the MAP2K3 and MAP2K6 are specific for 
p38, and the MAP2K1 and MAP2K2 are spe-
cific for ERK activation. 
Once activated, the MAPKs can translo-
cate to the nucleus, where they phosphorylate 
transcription factors causing gene expression 
changes. The activated MAPKs exhibit dis-
tinct specificity in nuclear transcription factor 
phosphorylation. For instance, JNKs are the 
upstream kinases for c-JUN, whereas both 
JNK and p38 can phosphorylate ATF2; the 
ERKs, on the other hand, specifically catalyze 
the phosphorylation of ELK1. Through the 
distinct connections to upstream regulators 
and downstream effectors, each MAPK exhib-
its unique roles in converting transient bio-
chemical signals to permanent changes of gene 
expression in the control of cell functions. 
The existing literature describes divergent 
effects of Cr(VI) on MAPK signaling, as acti-
vation patterns vary depending on different 
experimental systems, treatment concentra-
tions, time of exposure, and target cell type 
used for the studies (Chuang and Yang 2001; 
O’Hara et al. 2003; Samet et al. 1998; Tessier 
and Pascal 2006). Several studies show that 
high concentrations of Cr(VI) can activate 
all three MAP kinases and that the activation 
may be mediated via reactive oxygen species 
(ROS)-dependent mechanisms. Conversely, 
lower concentrations of Cr(VI) may activate 
selective MAPK subgroups in a highly cell-
type-specific fashion, whereas activation might 
be ROS independent. Induction of MAP 
kinase pathways was shown to contribute to 
specific toxic responses to Cr(VI) (Wakeman 
et al. 2005; Wang and Shi 2001), although 
in other cases could not be linked to a defined 
end point of Cr(VI) toxicity (Ceryak et al. 
2004; Chuang and Yang 2001). Collectively, 
these observations suggest that MAPK 
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Ba c k g r o u n d: Potassium dichromate [Cr(VI)] is a widespread environmental toxicant responsible 
for increased risk of several human diseases. Cr(VI) exposure leads to activation of mitogen-activated 
protein kinases (MAPKs), including c-Jun N-terminal kinase (JNK)1/2, p38, and extracellular-
  signal regulated kinase (ERK)1/2. 
oBjectives: We evaluated the contribution of MAPKs to Cr(VI) toxicity. 
Me t h o d s : Phosphorylation of MAPKs and their downstream effectors was evaluated by Western 
immunoblotting; reactive oxygen species were measured by DCFDA (5´,6´-chloromethyl-2´-7´-
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levels were determined by monochrome graphic spectroflurometer. Cytotoxicity was assessed by 
the MTS [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazo-
lium] assay and colony formation. Embryoid body (EB) differentiation was evaluated by contracting 
cardiomyocyte formation, and real-time polymerase chain reaction (RT-PCR) was used for cardio-
myocyte-specific and stem-cell-specific gene expression. 
re s u l t s: Acute treatment of mouse embryonic stem (ES) cells with 50 µM Cr(VI) induced the rapid 
phosphorylation of JNK, p38, and ERK and their respective downstream transcription factors, c-JUN, 
activating transcription factor-2, and ELK1. MAPK activation and cytotoxicity induction were par-
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activation and MAP2K4-dependent p38 activation and strongly inhibited contracting cardiomyocyte 
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co n c l u s i o n: Each MAPK distinctly contributes to chromium toxicity. Whereas JNK prevents and 
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activation is due to the combinatorial effects 
of Cr(VI) bioprocessing and dynamic interac-
tions of Cr species with other cellular com-
ponents within the local environment. As a 
consequence, the contribution of each MAPK 
pathway to chromium toxicity will be better 
evaluated individually in the specific cellular 
context and exposure condition. In this paper, 
we characterized the effects of high and low 
concentrations of Cr(VI) on MAPK activation 
profiles in wild-type (WT) and Map2k4(–/–) 
and Map2k7(–/–) embryonic stem (ES) cells. 
Using these cells, we show that Cr(VI) acti-
vates all three MAPKs, but each of them leads 
to specific transcription factor modifications 
and makes unique contributions to Cr(VI) 
cytotoxicity and differentiation inhibition. 
Materials and Methods
Reagents and antibodies. Dulbecco’s mini-
mum essential medium (DMEM), l-glu-
tamine, MEM nonessential amino acids, and 
penicillin-streptomycin were purchased from 
Mediatech (Manassas, VA); Eagle’s MEM was 
from Lonza Inc (Basel, Switzerland); ESGRO 
(LIF) was from Millipore (Temecula, CA); 
calcium chloride was from Cascade Biologics 
(Invitrogen; Carlsbad, CA); and fetal bovine 
serum (FBS) knockout serum replace-  (FBS) knockout serum replace-
ment, β-mercaptoethanol, and CM-H2 
5´,6´-chloromethyl-2´-7´-dichlorofluorescin 
diacetate (DCFDA) were purchased from 
Invitrogen. The chemical inhibitors for 
JNK (SP600125), p38 (SB202190), ERK 
(PD98059), and protein synthesis [cyclo-
heximide (CHX)] were from Calbiochem 
(Gibbstown, NJ); N-acetyl cysteine (NAC) 
and Cr(VI) were from Sigma (St. Louis, MO). 
Adenoviruses for GFP and MAP2K7 were 
as described previously (Deng et al. 2006). 
Antibodies for phospho-JNK (Thr-183, 
Tyr-185) and total JNK, phospho-p38 
(Thr-180, Tyr-182) and total p38, phospho-
ERK (Thr-202, Thr-204) and total ERK, as 
well as antibodies for phospho-c-Jun (Ser-63), 
phospho-ATF2 (Thr-69,71), poly-(ADP-
ribose) polymerase (PARP), MAP2K4, and 
MAP2K7 were purchased from Cell Signaling 
Technology (Danvers, MA); antibodies for 
total c-Jun, phospho-ELK1 (Ser-383), and 
c-FOS were from Santa Cruz Biotechnology 
(Santa Cruz, CA); anti  bodies for β-actin and 
active caspase-3 were from Pharmingen (San 
Diego, CA), and anti-GFP was from Roche 
(Palo Alto, CA). 
Cell culture and adenoviral infection. We 
precoated culture dishes used for mouse ES 
cells with 0.1% gelatin for 20 min. The ES 
cells of WT, Map2k4(–/–), and Map2k7(–/–) 
were maintained in ES complete medium, 
containing DMEM, 15% FBS knockout 
serum replacement, 2 mM l-glutamine, 
50 U/mL penicillin, 50 µg/mL streptomy-
cin, 1% nonessential amino acids, 0.1mM 
β-mercaptoethanol, and 103 units/µL LIF. 
We carried out infection of the ES cells with 
adenovirus as described previously (Deng et al. 
2006). At 48 hr after infection, we subjected 
the cells to subsequent treatments with Cr(VI) 
or harvested them for Western blot analyses. 
Cytotoxicity assay. Acute cytotoxicity 
assays were performed on ES cells seeded at 
1.5 × 104 cells/well on 96-well plates pre-
coated with 0.1% gelatin. We treated the cells 
with various concentrations of Cr(VI), and 
measured the cytotoxicity using Cell Titer 96 
AQueous One Solution [MTS; 3-(4,5-dimethyl-
thiazol-2-yl)-5-(3-carboxymethoxyphenyl)-
2-(4-sulfophenyl)-2H-tetrazolium] following 
the manufacture’s recommended procedures 
(Promega, Madison, WI). 
Chronic toxicity assay was performed as 
described (Franken et al. 2006). Briefly, we 
plated 5,000 ES cells onto gelatin pretreated 
6-mm plates in ES complete medium in 
the absence and presence of various doses of 
Cr(VI). Cells were allowed to grow for 7 days, 
and the ES complete medium was replenished 
every 3 days. We washed the colonies with 
phosphate-buffered saline, fixed, and stained 
them with 0.3% crystal violet mixed in 25% 
ethanol for 2 min and counted them under 
the microscope. We used three plates for each 
treatment condition.
Cell lysate preparation and immuno-
blotting. ES cells were challenged with Cr(VI) 
at various conditions described above. Cell 
lysates were prepared and subjected to SDS-
PAGE and transferred to nitrocellulose 
membranes for Western blotting analyses as 
described elsewhere (Peng et al. 2007). 
Cellular ROS and glutathione measure-
ment. We measured the ROS levels in the 
cells by CM-H2 DCFDA labeling, and identi-
fied the fluorescence-positive cells by FACS 
analyses as described previously (Peng et al. 
2007). Glutathione and glutathione disulfide 
(GSSG) levels were determined as detailed 
previously (Senft et al. 2002), with samples 
prepared in triplicate for statistical analysis.
Differentiation of ES cells into contracting 
myocardial cells. We conducted cardiac dif-
ferentiation of ES cells as described previously 
(Gribaldo et al. 2002). On day 0, we aggregated 
ES cells (5 × 104 cells/mL) by culturing in 20-µL 
hanging drops in cell culture medium with-
out LIF. On day 3, the cell aggregates formed 
embryoid bodies (EBs), and the EBs were trans-
ferred to 24-well plates at 1 EB/well. On day 14, 
we counted the number of EBs with contracting 
myocardial areas under light microscopy. In 
some experiments, Cr(VI) was included in the 
growth medium for the entire time of differ-
entiation. We replenished the culture medium 
with or without chemicals every 3 days. 
Real-time polymerase chain reaction. We 
isolated total cellular RNA from WT and 
Map2k7(–/–) ES cells and EBs, which were 
allowed to differentiate for 14 days in the 
absence and presence of 0.1 µM Cr(VI). We 
performed cDNA preparation and real-time 
PCR as described previously (Peng et al. 
2007). Primers for mouse stem-cell-specific 
genes, Notch-1: 5´-AAT CTT GTC CAG 
ACA GGT GCC AGA and 5´-TCT GCT 
TAT GCC TCA AGG GAA CCA, Sox-2: 
5´-AAA GGA GAG AAG TTT GGA GCC 
CGA and 5´-GGG CGA AGT GCA ATT 
GGG ATG AAA, Oct-4: 5´-GGC GTT CTC 
TTT GGA AAG GTG TTC and 5´-CTC 
GAA CCA CAT CCT TCT CT and Nanog: 
5´-AGG GTC TGC TAC TGA GAT GCT 
CTG and 5´-CAA CCA CTG GTT TTT 
CTG CCA CCG; for cardiomyocyte-specific 
genes, Mhca: 5´-CTG CTG GAG AGG TTA 
TTC CTC G and 5´-GGA AGA GTG AGC 
GGC GCA TCA AGG and Mhcb: 5´-TGC 
AAA GGC TCC AGG TCT GAG GGC 
and 5´-GCC AAC ACC AAC CTG TCC 
AAG TTC; and for housekeeping genes, 
Actinb: 5´-TCT TGG GTA TGG AAT CCT 
GTG GCA and 5´-TCT CCT TCT GCA 
TCC TGT CAG CAA and Gapdh: 5´-TCA 
ACA GCA ACT CCC ACT CTT CCA and 
5´-ACC CTG TTG CTG TAG CCG TAT 
TCA were used for RT-PCR.
Statistical analyses. We conducted statisti-
cal comparisons using Student two-tailed paired 
t-test and analysis of variance. We considered 
values of p < 0.05 statistically significant. 
Results
High-concentration Cr(VI) activates MAPKs 
and downstream transcription factors in 
mouse ES cells. We examined MAPK activa-
tion in mouse ES cells treated with Cr(VI) 
at 50 µM for various lengths of time. Cr(VI) 
caused early and delayed ERK activation, as 
indicated by phospho-ERK2 (p42) induc-
tion, and delayed JNK and p38 activation, as 
indicated by the appearance of phospho-JNK 
(p54 and p46) and phospho-p38 (Figure 1A). 
Correspondingly, Cr(VI) induced the MAPK 
downstream events, including phosphory-
lation of c-JUN, ATF2, and ELK1 in WT 
ES cells (Figure 1B). In addition, there was 
an apparent elevation of c-JUN and c-FOS 
proteins at the delayed phase of exposure 
(Figure 1D). 
In recent years, genetic inactivation of 
MAP2Ks has been shown to specifically block 
MAP kinase activation, and the MAP2K-
deficient cells are used to sort out the roles of 
the MAPKs in variety of cell functions (Wada 
et al. 2008). We examined MAPK activa-
tion by Cr(VI) in the MAP2K4-deficient 
and MAP2K7-deficient ES cells (Figure 1C). 
Cr(VI) exposure did not alter MAP2K4/
MAP2K7 expression. Compared with the 
induction in the WT cells, p-JNK and p-p38 
induction by Cr(VI) in the Map2k4(–/–) cells 
was almost completely abolished [Figure 1A; Chen et al.
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see Supplemental Material, Figure 1 (avail-
able online at http://www.ehponline.org/
members/2009/0800157/suppl.pdf)]. 
Correspondingly, there were no detectable 
p-c-JUN and activating transcription fac-
tor-2 (p-ATF-2) in the Map2k4(–/–) cells 
[Figure 1B; see Supplemental Material, 
Figure 1 (http://www.ehponline.org/mem-
bers/2009/0800157/suppl.pdf)]. The phos-
phorylation of JNK and c-JUN was markedly 
suppressed in the Map2k7(–/–) cells, whereas 
the phosphorylation of p38 and ATF-2 was 
unaffected. The phosphorylation of ERK and 
ELK1 were not overtly affected by MAP2K4-
ablation and MAP2K7-ablation, indicating 
that these MAP2Ks were not essential for 
ERK pathway activation by Cr(VI) (Figures 
1A and 1B). Based on these observations, we 
conclude that the Cr(VI) signals that acti-
vate JNK are mediated by both MAP2K4 
and MAP2K7 and those that activate p38 by 
MAP2K4; however, neither MAP2K4 nor 
MAP2K7 are required for ERK activation and 
the induction of c-JUN and c-FOS expression 
(Figure 1D).
MAP2K7 and JNK reduce, but p38 
promotes, cytotoxicity induced by high con-
centration of Cr(VI). Cr(VI) cytotoxicity 
in WT ES cells depended on concentration 
and time of exposure and was significantly 
increased by treatment with 50 µM Cr(VI) 
for ≥ 6 hr [see Supplemental Material, 
Figures 1 and 2 (http://www.ehponline.org/
members/2009/0800157/suppl.pdf)]. In com-
parison with WT cells, Map2k4(–/–) cells had 
a slight but insignificant reduction of cyto-
toxicity. Conversely, Map2k7(–/–) cells had a 
marked increase in cytotoxicity (Figure 2A). 
The increased cytotoxicity of Map2k7(–/–) cells 
correlated with higher levels of PARP cleavage 
and active forms of caspase-3, both markers of 
apoptosis activation (Figures 2B and 2C). 
To confirm that MAP2K7 conferred 
resistance to Cr(VI) cytotoxicity, we over-
expressed MAP2K7 in Map2k7(–/–) cells 
using an adenovirus-mediated gene delivery 
system. At 48 hr of infection, the levels of 
MAP2K7 in Ad-MAP2K7-infected, but not 
Ad-GFP infected, Map2k7(–/–) cells were simi-
lar to or even higher than those in the WT 
cells (Figure 2D). When exposed to Cr(VI), 
the Ad-MAP2K7-infected Map2k7(–/–) cells 
reached a survival rate similar to that of the 
WT cells, much higher than the parental unin-
fected or Ad-GFP-infected cells (Figure 2E). 
To test whether MAPK activation was 
responsible for Cr(VI) cytotoxicity, we treated 
the WT ES cells with specific MAPK inhibitors 
prior to Cr(VI) exposure. Our previous work 
had established that at 5 µM concentration 
short-term treatment, SP600125 was specific 
for JNK inhibition, and similarly, SB202190 
was specific for p38 and PD98059 for ERK 
(Deng et al. 2006). Whereas inhibition of JNK 
sensitized the cells to Cr(VI) cytotoxicity, inhibi-
tion of p38 reduced it, and inhibition of ERK 
had no effect (Figure 2F). Furthermore, pre-
treatment of cells with CHX to inhibit protein 
synthesis significantly reduced, but did not com-
pletely prevent, Cr(VI) cytotoxicity in WT ES 
cells (Figure 2F), suggesting that gene transcrip-
tion and de novo protein synthesis contribute 
partially to Cr(VI) cytotoxicity. Considering 
that Map2k7(–/–) cells are defective in JNK 
activation and are more sensitive to Cr(VI) cyto-
toxicity, a condition similar to that of WT cells 
treated with the JNK inhibitors, we suggest that 
JNK activation is required for reducing Cr(VI) 
cytotoxicity. On the other hand, cells treated 
with the p38 inhibitor and Map2k4(–/–) cells, 
defective in p38 activity, are both somewhat 
Cr-resistant, suggesting that p38 activation may 
augment Cr(VI) cytotoxicity. 
N-acetyl cysteine partially blocks high-
concentration Cr(VI)-induced MAPK activa-
tion and cytotoxicity. It has been suggested 
that Cr(VI) can activate MAPKs via ROS-
dependent and ROS-independent mecha-
nisms (Kim and Yurkow 1996; O’Hara 
et al. 2003). We labeled the WT ES cells, 
either untreated or treated with Cr(VI) and 
H2O2, with ROS-activated fluorescent dye 
CM-H2DCFDA and measured intracellular 
ROS levels by flow cytometry. Compared 
with the untreated cells, ROS accumulation 
was higher in Cr(VI)-treated cells, but the lev-
els induced by Cr(VI) were lower than those 
induced by H2O2 (Figure 3A). Map2k4(–/–) 
and Map2k7(–/–) ES cells displayed similar 
patterns of ROS induction by Cr(VI) [see 
Supplemental Material, Figure 4 (http://www.
ehponline.org/members/2009/0800157/
suppl.pdf)]. To further evaluate the ROS 
induction by Cr(VI), we measured the expres-
sion of heme oxygenase-1 (HO-1), a known 
marker of cellular oxidative stress. Cr(VI), in 
an exposure time-dependent manner, caused 
an apparent HO-1 induction, which was par-
tially blocked by pretreatment with NAC, an 
antioxidant that elevates glutathione (GSH) 
and prevents ROS accumulation (Figures 3B 
Figure 1. High-concentration Cr(VI) induces MAPK activation in WT, Map2k4(–/–), and Map2k7(–/–) mouse ES cells. WT, Map2k4(–/–), and Map2k7(–/–) cells were 
treated with 50 µM Cr(VI) for various times as indicated. Cell lysates were subjected to Western blot analysis for (A) phospho-JNK and total JNK, p38, and ERK; 
(B) phospho-c-JUN, ELK1, and ATF2; (C) total MAP2K4, MAP2K7, and actin; and (D) total c-JUN and c-FOS. Arrowheads point to specific MAPK isoforms. The 
ratio of phosphoprotein versus total protein or actin was calculated in each sample and the fold induction was calculated in comparison with the untreated con-
trol of the same cell type. Images shown in this figure are representative of at least two independent results. 
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and 3C). Cellular redox homeostasis is largely 
dependent on GSH, which when oxidized by 
ROS, forms GSSG. We found higher GSSG 
in ES cells treated by Cr(VI) than in untreated 
cells, further supporting the idea that Cr(VI) 
induced oxidative stress and caused GSH 
depletion (Figure 3D)
To test whether NAC can prevent MAPK 
activation and cytotoxicity in our system, we 
treated WT cells with NAC prior to Cr(VI) 
exposure. In NAC pretreated cells, there was a 
significant decrease in the induction of p-JNK, 
p-p38, and p-ERK by Cr(VI) at the late expo-
sure times (6 hr), but induction of p-ERK 
at early times (10 min) did not seem to be 
affected (Figure 3E). Induction of the nuclear 
factors p-JUN, p-ATF2, and c-FOS was also 
significantly reduced by NAC pretreatment 
(Figure 3F). Moreover, NAC significantly pre-
vented Cr(VI) cytotoxicity as measured by 
both the acute and chronic toxicity (Figures 
3G and 3H). Protection by NAC was much 
more effective than by MAPK inhibitors or by 
MAP2K gene ablation, indicating that NAC 
offers a broader protection against Cr(VI) 
cytotoxicity and that one of the downstream 
events of NAC may be to reduce the delayed 
MAPK activation. 
The role of MAPKs in low-concentra-
tion Cr(VI) effects. Having established the 
MAPK activation patterns in response to high 
Cr(VI) concentrations, we asked whether 
the MAPKs, particularly JNK and p38, were 
similarly affected by MAP2K4/MAP2K7 
ablation in response to low concentrations 
of Cr(VI), more comparable with potential 
environmental or occupational human expo-
sures. We treated the ES cells with 0.1 µM 
Cr(VI) for various times ranging from 1 to 
10 days and examined the phospho-JNK 
and total-JNK and p38 (Figure 4A). Low-
concentration Cr(VI) caused a clear induc-
tion of p-JNK in WT ES cells. In contrast to 
high-concentration Cr(VI), which strongly 
induced phosphorylation of both p46 and 
p54 JNK isoforms (Figure 1A), low-concen-
tration Cr(VI) only weakly activated the p46 
JNK isoform. Similarly, low-concentration 
Cr(VI) induced weaker and delayed p38 
phosphorylation. JNK activation by low-con-
centration Cr(VI) was completely abolished 
in Map2k4(–/–) and Map2k7(–/–) cells, whereas 
p38 activation was unaffected in Map2k7(–/–) 
but blocked in Map2k4(–/–) cells, similar to 
the activation patterns in response to high 
concentration (Figure 1A). 
We next examined the contributions of 
MAPKs to chronic toxicity of Cr(VI) using 
colony formation assays (Figure 4B). In com-
parison with the WT ES cells, Map2k4(–/–) 
cells showed significantly higher chronic sur-
vival rate in response to 1 µM Cr(VI) treat-
ment for 7 days, whereas Map2k7(–/–) cells 
had markedly decrease survival rate. Based 
on these observations, we conclude that, like 
high-concentration Cr(VI), low concentra-
tion activates JNK through MAP2K4/7 and 
p38 through MAP2K4 in ES cells and that 
MAP2K4 and MAP2K7 have similar effect 
on the cytotoxicity of low and high concen-
trations of Cr(VI).
Suppression of ES cell differentiation by 
chromium requires MAP2K7. Developing 
rhythmically contractile cardiomyocytes from 
EBs were used to evaluate the developmental 
effects of MAPKs and Cr(VI). Although 30% 
of WT EBs and 60% of MAP2K7-deficient 
EBs developed rhythmic contractile cardio-
myocytes, none of the MAP2K4-deficient 
EBs formed them (Figure 5A and data not 
shown). Because p38 α-deficient ES cells have 
failed cardiomyocyte differentiation, it is pos-
sible that the MAP2K4-deficient cells lack 
p38 activation and therefore have a defective 
cardiac differentiation (Aouadi et al. 2006). 
Cr(VI) at 1 µM completely abolished WT 
EB to form contractile cardiomyocytes, but at 
0.01 µM had no effect at all (data not shown). 
At 0.1 µM, Cr(VI) caused a 95% suppression 
of cardiac differentiation in WT EBs, but less 
than 50% suppression in MAP2K7-deficient 
EBs. Based on these evaluations, we conclude 
that MAP2K7 inactivation might offer protec-
tion against Cr(VI) toxicity in the inhibition 
of ES cell differentiation (Figures 5A and 5B). 
To study EB differentiation at the molec-
ular level, we examined the expression of 
stem-cell-specific and cardiomyocyte-specific 
markers by RT-PCR. Compared with undif-
ferentiated ES cells, the differentiated WT and 
Map2k7(–/–) EBs had decreased expression of 
stem-cell-specific genes, such as Notch, Sox-2, 
Nanog, and Oct-4, but elevated expression of 
cardiomyocyte genes, such as MhcA and MhcB, 
indicative of cardiomyocyte differentiation 
(Figures 5C and 5D). Such changes in gene 
expression were clearly suppressed by Cr(VI) 
in WT but not in Map2k7(–/–) EBs. Thus, this 
Figure 2. MAP2K7 and JNK protect cells from cytotoxicity from high-concentration Cr(VI). WT, Map2k4(–/–), 
and Map2k7(–/–) ES cells were treated with 50 µM Cr(VI) for different times as indicated. (A) MTS assay 
was performed to evaluate cell survival. Cell lysates were subjected to Western blotting to monitor the 
levels of apoptotic markers; (B) PARP cleavage and (C) active caspase-3. Map2k7(–/–)cells were infected 
with adenoviruses for either GFP or MAP2K7 at 100 pfu/cell. At 48 hr of infection, (D) the expression of 
MAP2K7, GFP, and actin in WT, Map2k7(–/–), and Map2k7(–/–) adenoviral-infected cells were examined by 
Western blotting. (E) WT, Map2k7(–/–), and Map2k7(–/–) adenoviral-infected cells were treated with 50 µM 
Cr(VI) for 10 hr. Cell survival was determined by MTS assays, and each value was presented as mean ± SD 
from four replicates. (F) WT ES cells were pretreated with chemical inhibitor for JNK (SP60015, 5 µM), p38 
(SB202190, 5 µM), ERK (PD98059, 5 µM), and protein synthesis (CHX, 1 µg/mL) for 1 hr. The cells were incu-
bated with Cr(VI) at 50 µM for 8 hr. Cell survival rates were analyzed by MTS assay, and each value was 
presented as mean ± SD from four replicates. 
**p < 0.01. #p < 0.001. 
Control
WT M4 M7 M7 M4 WT
WT
–
–
–– –
–– –
–– +
++
+
+
++ ++
+
+
+
+ +
+ –
–– ––
––––
––––
–––
+
–– +
Map2k7(–/–)
Cr
 MAP2k4(–/–)
 MAP2k7(–/–)
 Ad-MAP2k7
 Ad-GFP
 MAP2k7
GFP
Actin
0 Time (min)
Time (hr)
WT
Actin
Cleaved
caspase 3
Cr Cr
SP
SB
PD
CHX
Ad-GFP
Ad-MAP2K7
WT
Map2k4(–/–)
Map2k7(–/–)
V
i
a
b
i
l
i
t
y
 
(
%
 
r
e
l
a
t
i
v
e
 
t
o
 
u
n
t
r
e
a
t
e
d
 
c
e
l
l
s
)
V
i
a
b
i
l
i
t
y
 
(
%
 
r
e
l
a
t
i
v
e
 
t
o
 
u
n
t
r
e
a
t
e
d
 
c
e
l
l
s
)
V
i
a
b
i
l
i
t
y
 
(
%
 
r
e
l
a
t
i
v
e
 
t
o
 
u
n
t
r
e
a
t
e
d
 
c
e
l
l
s
)
01 0
#
#
48
10 30 360 120
PARP
PARP
PARP
cPARP
cPARP
cPARP
120
100
80
60
40
20
0
80
60
40
20
0
80
60
40
20
0
** #
#
# **
Map2k7(–/–) WTChen et al.
1128  v o l u m e  117 | n u m b e r 7 | July 2009  •  Environmental Health Perspectives
gene expression signature also suggests that 
MAP2K7 inactivation prevents the inhibitory 
effects of Cr(VI) on ES cell differentiation. 
Discussion
Cr(VI) exposure is associated with broad 
classes of adverse health effects in humans 
and in animal models, including respiratory 
cancer, impaired organ function, immune 
system defects, birth defects, and decreased 
fertility (Junaid et al. 1996; Kanojia et al. 
1998; Salnikow and Zhitkovich 2008), but 
the molecular mechanisms underlying disease 
development are not well understood. In the 
present studies, we show that one consequence 
of Cr(VI) exposure of mouse ES cells is the 
early and delayed activation of MAPKs. There 
is a good correlation between the MAPKs and 
their corresponding downstream transcription 
factor modifications. These results, together 
with the findings that Cr(VI) cytotoxicity 
requires de novo protein synthesis, indicate 
that the MAPKs may activate transcriptional 
programs for gene expression, which in turn 
influences cell fate determination in response 
to Cr(VI) (Figure 6).
Similar MAPK induction by Cr(VI) has 
been observed in various cells types (Ceryak 
et al. 2004; Chuang and Yang 2001; O’Hara 
et al. 2003; Samet et al. 1998; Tessier and 
Pascal 2006; Wakeman et al. 2005), but the 
specific contributions of the different MAPKs 
to Cr(VI) toxicity are poorly defined. Studies 
based solely on pharmaceutical MAPK inhibi-
tors used at high concentrations that have been 
shown to cause nonspecific effects (Tan et al. 
2002) often generate diametrically opposite 
results (Chuang and Yang 2001; Wakeman 
et al. 2005). We used instead the combined 
approach of MAP2K-deficient cells and low-
dose MAPK inhibitors for short-term treat-
ment to reveal the distinct contributions each 
MAPK makes to acute Cr(VI) cytotoxicity. 
We show that JNK alleviates, p38 promotes, 
and ERK has no obvious effect on cytotoxic-
ity of Cr(VI) at high and low concentrations 
(Figure 6). Antagonistic roles of JNK and p38 
have been described previously, in that JNK 
positively regulates proliferation and oncogenic 
transformation but negatively regulates cellular 
senescence, whereas p38 suppresses prolifera-
tion and transformation but potentiates cellular 
senescence (Wada et al. 2008). Our studies for 
the first time report opposing effects of JNK 
and p38 exist for Cr(VI) cytotoxicity. 
In addition to its acute cytotoxicity, Cr(VI) 
is a known developmental toxicant, causing 
postimplantation losses, resorptions, reduced 
fetal weight, and malformations includ-
ing reduced ossification (Junaid et al. 1996; 
Kanojia et al. 1998). We have found that 
Cr(VI) is a strong developmental toxicant that, 
at concentrations as low as 0.1 µM, causes 
95% inhibition of cardiac differentiation of 
EBs, corresponding to the repression of cardio-
myocyte-specific gene induction. This observa-
tion is in general agreement with the findings 
by Stummann et. al. showing that 1.8 µM 
Cr(VI) causes 50% inhibition of the cardiac 
differentiation of D3 ES cells (Stummann 
et al. 2007). However, the ES cell lines used in 
our studies appear to be even more sensitive to 
Cr(VI), perhaps because they originated from 
the Sv129 mouse strain. 
Figure 3. NAC suppresses MAPK activation and cytotoxicity induced by high-concentration Cr(VI). (A) WT 
ES cells were treated with 50 µM Cr(VI) for 6 hr or 50 µM H2O2 for 2 hr. The cells were labeled with 10 µM 
CM-H2DCFDA for 30 min and were subjected to flow cytometric analysis. DCF-positive cells were identified 
by CellQuest analysis. Cells were either pretreated with 5 mM NAC for 4 hr or left untreated prior to expo-
sure to 50 µM Cr(VI) for various times. (B) Western blotting was used to measure the expression of HO-1 
and actin in WT ES cells treated with Cr(VI) 50 µM for various times. (C) The relative levels of HO-1 protein 
expression were quantified by gel imaging in ES cells with or without NAC and Cr(VI) treatment. (D) Cells 
exposed to Cr(VI) at 50 µM for various times were analyzed for the cellular level of GSSG. Western blot 
was done to measure (E) phosphorylated and total JNK, p38, and ERK and (F) p-JUN, p-ATF2, c-FOS, and 
actin. The results were quantified by chemiluminescence imaging and the fold induction of p-JNK over 
JNK, p-38 over P38, p-ERK over ERK, and p-c-Jun, p-ATF2, and c-Fos over actin was calculated. (G) WT, 
Map2k4(–/–), and Map2k7(–/–) ES cells were either pretreated with 5 mM NAC for 4 hr or left untreated prior 
to exposure to 50 µM Cr(VI) for 8 hr. Cell survival was measured by the MTS assay. (H) WT cells were 
exposed to 1 µM or 10 µM Cr(VI) in the presence or absence of 5 mM NAC. Colonies were counted on day 
8 of treatment. The values in B, D, and E are shown as mean ± SD from at least three experiments. The 
ratio of phosphoprotein versus total protein or actin was calculated in each sample, and the fold induction 
was calculated in comparison with the untreated control of the same cell type. 
*p < 0.05. **p < 0.01. #p < 0.001. 
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Although the chemical inhibitors for short-
term treatment can effectively block MAPK 
activity and cytotoxicity of chromium, the JNK 
inhibitor SP600125 completely abrogated the 
EB formation when used for a longer treat-
ment period (data not shown). These observa-
tions suggest that long-term application of these 
chemicals may exhibit nonspecific toxicity irrel-
evant to JNK inhibition, because in vivo JNK1/
JNK2 double ablation does not cause global 
differentiation defects (Kuan et al. 1999). 
Because JNK is the only known down-
stream target of MAP2K7, the Map2k7(–/–) 
cells have been conveniently used to evaluate 
physiologic consequences of JNK loss of func-
tion (Wada et al. 2008). Indeed, we show that 
JNK is the sole MAPK whose activation by 
Cr(VI) is effectively abrogated in Map2k7(–/–) 
ES cells. Intriguingly, Cr(VI) causes only a 
slight suppression of contractile cardiomyocyte 
formation in the Map2k7(–/–) EBs and does not 
cause reduction of cardiomyocyte-specific gene 
expression in these cells. Because Cr(VI) fails to 
activate JNK in Map2k7(–/–) cells, it is possible 
that blocking JNK reduces Cr(VI) toxicity on 
the inhibition of cardiomyocyte differentiation. 
The seemingly contrasting role that the JNK 
pathway appears to have by inhibiting cardio-
myocyte differentiation on the one hand and 
preventing acute and chronic cytotoxicity on 
the other is not entirely surprising, because 
the JNK pathway is known to regulate diverse 
transcriptional programs, participating in a 
broad spectrum of cell responses. 
The MAP2Ks are immediately upstream 
kinases responsible for MAPK phosphoryla-
tion and activation. It has been shown that 
MAP2K4 and MAP2K7 distinctly phos-
phorylate JNK at tyrosine and threonine, 
respectively (Lawler et al. 1998). We find 
that Cr(VI) reduces JNK phosphorylation 
and completely abolished c-JUN phosphory-
lation in Map2k4(–/–) and Map2k7(–/–) cells. 
This observation seems to support the notion 
that MAP2K4 and MAP2K7 phosphorylate 
distinct sites at the Thr-X-Tyr motif of JNK 
and that phosphorylation of both tyrosine and 
threonine residues is required for optimal JNK 
activity in c-JUN phosphorylation. Besides 
JNK activation, MAP2K4 is also known to 
activate p38. In ES cells, MAP2K4 appears to 
Figure 4. MAPK activation and cytotoxicity in response to low-concentration Cr(VI). (A) WT, Map2k4(–/–), and Map2k7(–/–) ES cells were treated with 0.1 µM Cr(VI) as 
indicated. Cell lysates were used for Western blot analyses for the phospho-JNK and total JNK and p38. Arrowheads point at different JNK isoforms. The ratio of phos-
phoprotein versus total protein was calculated in each sample, and the fold induction was calculated in comparison with the untreated control of the same cell type. 
(B) Cells were treated with 0.1 µM or 1 µM Cr(VI) for 7 days, and colonies were counted on day 8 of treatment. Each value represents the mean ± SD from six replicates. 
*p < 0.05. 
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Figure 5. MAP2K7-deficient cells are resistant to Cr(VI) developmental toxicity. WT and Map2k7(–/–) EBs were grown in the presence or absence of 0.2 µM Cr(VI) 
for 8–13 days. The percentage of EBs that developed rhythmic beating cardiomyocytes (A) and the percentage inhibition of beating cardiomyocytes formation by 
Cr(VI) (B) were calculated. The values are shown as mean ± SD from at least three experiments. In WT (C) and Map2k7(–/–) (D) EBs, the relative levels of stem-
cell-specific and cardiomyocyte-specific genes over Gapdh were calculated. The values are shown as mean ± SD from at least three experiments. 
**p < 0.01. 
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be essential for p38 activation by Cr(VI), even 
though these cells have other p38 MAP2Ks, 
such as MAP2K3 and MAP2K6 (data not 
shown). It remains to be determined, however, 
whether MAP2K4 activates p38 directly or 
indirectly through the activation of MAP2K3/6 
in the transmission of Cr(VI) signals. Under 
in vivo physiologic conditions, the MAP2K4 
and MAP2K7 have nonredundant roles in fetal 
liver development (Wang et al. 2007). Our 
in vitro studies show that Map2k4(–/–) ES cells 
fail to develop beating cardiomyocytes. On the 
other hand, Map2k7(–/–) ES cells form beating 
cardiomyocytes more efficiently than the WT 
cells, suggesting that MAP2K7 suppresses car-
diac differentiation. 
Cr(VI) undergoes intracellular reduction, 
resulting in the generation of toxic Cr interme-
diates and thermodynamically stable Cr(III), 
which are ultimately responsible for DNA 
damage (Salnikow and Zhitkovich 2008), 
and of ROS, which contribute to cytotoxic-
ity. Cr(VI) reduction is carried out by cellular 
antioxidant systems such as glutathione and 
ascorbate. Ascorbate has been shown to increase 
Cr(VI) reductive activation, enhance toxicity, 
and potentiate mutagenicity, suggesting that 
ascorbate, commonly used as a redox scaven-
ger to prevent toxicity of other environmental 
agents, is not suitable for counteracting Cr(VI) 
toxicity (Salnikow and Zhitkovich 2008). We 
find that incubation of cells in ascorbate at 
1 mM for a shorter time (< 12 hr) offers no 
protection against Cr(VI) cytotoxicity, but for 
a long time (> 20 hr) is by itself toxic to ES 
cells even in the absence of Cr(VI) (data not 
shown). This observation precludes the pos-
sibility of further evaluating the role of ascor-
bate in Cr(VI) cytotoxicity in our experimental 
systems. On the other hand, NAC exhibits a 
remarkable protection against Cr(VI) cytotox-
icity. Furthermore, inclusion of 5 mM NAC 
in the growth medium does not completely 
abrogate, but significantly reduces, the delayed 
MAPK activation by Cr(VI). There are mul-
tiple possibilities for NAC to exert protection, 
including potentiation of Cr(VI) extracellular 
bioreduction, elevation of intracellular GSH to 
promote the removal of ROS, and promotion 
of electron transfer for direct Cr(VI) intracellu-
lar reduction (Guttmann et al. 2008; Salnikow 
and Zhitkovich 2008), all of which could be 
the reason for NAC to decrease Cr(VI)-induced 
MAPK activity. It is worth noting that EB and 
contractile cardiomyocyte formation are com-
pletely abrogated in the presence of 0.5 mM 
NAC in the medium (data not shown), indicat-
ing that excess cysteine can also disrupt normal 
ES cell differentiation programs. 
Our understanding of the molecular 
events mediating cellular responses to Cr(VI) 
is rapidly expanding. In addition to causing 
DNA damage and modifying chromatin, 
Cr(VI) can induce MAPKs to affect the well-
being of the organism. Moreover, we find that 
each MAPK member makes a distinct contri-
bution to Cr(VI) cytotoxicity and inhibition 
of differentiation (Figure 6). The experimen-
tal systems described in our studies may pro-
vide useful tools to evaluate the contributions 
of the MAPK members to other Cr(VI) toxic 
end points, such as cell cycle progression, dif-
ferentiation, development, and movement.
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Figure 6. Distinct contributions of JNK and p38 to 
Cr(VI) toxicity. Cr(VI) induced the activation of the 
MAPKs via multiple mechanisms that can be ROS 
dependent and independent. The activation of JNK 
and p38, but not ERK, is mediated through MAP2K4 
and MAP2K7. Specifically, MAP2K4 and MAP2K7 
both are required for optimal JNK activation, but 
only MAP2K4 is essential for p38 activation. Using 
cells deficient in MAP2K4 and MAP2K7, we were 
able to delineate the distinct roles JNK and p38 
play in the cytotoxicity and developmental toxicity 
of chromium. 
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